Pharvaris (PHVS) Share-based Compensation (2020 - 2026)
Pharvaris' (PHVS) quarterly Share-based Compensation came in at $5.7 million in Q1 2026, up 32.07% YoY from $4.3 million in Q1 2025, and up 8.56% on a QoQ basis from $5.3 million in Q4 2025.
Pharvaris (PHVS) Share-based Compensation (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Share-based Compensation data on file, last reported at $5.7 million in Q1 2026.
- Quarterly Share-based Compensation rose 32.07% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (up 19.05% YoY) and the FY2025 annual result came in at $21.5 million, up 22.69% from the prior year.
- Share-based Compensation grew to $5.7 million in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5771.1 billion in Q2 2023 to a low of -$5769.3 billion in Q3 2023.
- A 5-year average of $108.1 million and a median of $4.2 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 172087079.47% in 2023, down 187987220.43% in 2023.
- Tracing PHVS's Share-based Compensation over 5 years: stood at $3.3 million in 2022, then dropped by 18.73% to $2.7 million in 2023, then jumped by 93.92% to $5.2 million in 2024, then gained by 2.16% to $5.3 million in 2025, then advanced by 8.56% to $5.7 million in 2026.
- The last three Share-based Compensation figures came in at $5.7 million (Q1 2026), $5.3 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.73 Mn |
| Mar 31, 2026 | 5.73 Mn |
| Dec 31, 2025 | 5.28 Mn |
| Dec 31, 2025 | 5.28 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.34 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.58 Mn |
| Sep 30, 2024 | 5.58 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 4.19 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Dec 31, 2023 | 2.67 Mn |